Annual Securities Report — FY2025
What ZERIA PHARMACEUTICAL CO.,LTD. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-25View the original on EDINET
How much it says
61Detailed
What moved here
30named for the first time
Its own wording
72terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The annual securities report for the consolidated fiscal year from 1 April 2025 to 31 March 2026 was filed, reporting sales and profit, segment performance, cash flows, capital expenditures and R&D activities. The most notable event was the impact of the absorption-type merger of Kenso Pharmaceutical Co., Ltd. dated 1 April 2025, which is reflected in the scope of consolidation and related disclosures.
Komori's summary of this document, not the document's own words.61Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
68
Detailed
100
Very detailed
62
Detailed
25
Almost nothing
50
Typical
68
Detailed
37
Thin
48
Typical
60
Detailed
55
Typical
73
Detailed
R&D spend37億円Money spent making new things.
Cash left over102億円Cash from the business, less what went into equipment.
Spent on equipment22億円Plants, machines — things meant to last.
Employees1,748Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.